Table 3a.
PFS | OS | |||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
ECOG PS | ||||
≥2 vs. 0–1 | 1.67 (1.1–2.5) | 0.004 | 2.08 (1.37–3.16) | 0.001 |
No. of metastatic sites | ||||
≥3 vs. <3 | 1.7 (1.2–2.3) | 0.004 | 2.36 (1.62–3.45) | <0.001 |
No. of prior therapies | ||||
≥3 vs. <3 | 1.57 (1.1–2.3) | 0.014 | 1.73 (1.16–2.6) | 0.008 |
Type of ICI therapy | ||||
Combination vs. single-agent | NA | NA | 0.7 (0.5–1.07) | 0.096 |